EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
18 nov. 2024 07h00 HE
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of...
EyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Developments
07 nov. 2024 07h00 HE
|
EyePoint Pharmaceuticals, Inc.
– Announced positive interim data for DURAVYU 2.7mg in DME demonstrating meaningful, early and sustained visual acuity gains, strong anatomical control and a continued favorable safety profile; BCVA...
EYEPOINT ALERT: Bragar Eagel & Squire, P.C. is Investigating EyePoint Pharmaceuticals, Inc. on Behalf of EyePoint Stockholders and Encourages Investors to Contact the Firm
28 déc. 2022 23h25 HE
|
Bragar Eagel & Squire
NEW YORK, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against EyePoint Pharmaceuticals,...
EYEPOINT ALERT: Bragar Eagel & Squire, P.C. is Investigating EyePoint Pharmaceuticals, Inc. on Behalf of EyePoint Stockholders and Encourages Investors to Contact the Firm
23 déc. 2022 21h09 HE
|
Bragar Eagel & Squire
NEW YORK, Dec. 23, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against EyePoint Pharmaceuticals,...
EYEPOINT ALERT: Bragar Eagel & Squire, P.C. is Investigating EyePoint Pharmaceuticals, Inc. on Behalf of EyePoint Stockholders and Encourages Investors to Contact the Firm
16 déc. 2022 23h03 HE
|
Bragar Eagel & Squire
NEW YORK, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against EyePoint Pharmaceuticals,...
Bragar Eagel & Squire, P.C. Is Investigating GrafTech, BRP, Cantaloupe, and EyePoint and Encourages Investors to Contact the Firm
12 déc. 2022 22h46 HE
|
Bragar Eagel & Squire
NEW YORK, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against GrafTech International...
Bragar Eagel & Squire, P.C. Is Investigating GrafTech, BRP, Cantaloupe, and EyePoint and Encourages Investors to Contact the Firm
02 déc. 2022 20h45 HE
|
Bragar Eagel & Squire
NEW YORK, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against against GrafTech...
Bragar Eagel & Squire, P.C. Is Investigating EyePoint, F45, PROG, and Establishment and Encourages Investors to Contact the Firm
21 nov. 2022 20h45 HE
|
Bragar Eagel & Squire
NEW YORK, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against EyePoint Pharmaceuticals,...
Bragar Eagel & Squire, P.C. Is Investigating EyePoint, F45, PROG, and Intuit and Encourages Investors to Contact the Firm
11 nov. 2022 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against EyePoint Pharmaceuticals,...
Bragar Eagel & Squire, P.C. Is Investigating Cantaloupe, EyePoint, Spectrum, and F45 Training and Encourages Investors to Contact the Firm
06 nov. 2022 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, Nov. 06, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Cantaloupe, Inc. (NASDAQ:...